Future Directions for Precision Medicine in Advanced NSCLC

Future Directions for Precision Medicine in Advanced NSCLC

Episodes

Specialty:

All

Year:

All

EP. 1: Advances in Frontline Therapy for EGFR+ NSCLC

October 23rd 2018

EP. 2: Resistance Mechanisms and Sequencing for EGFR+ NSCLC

October 23rd 2018

EP. 3: Promising EGFR Inhibitors in Development for NSCLC

October 23rd 2018

EP. 4: Frontline Chemo and TKI Combination in EGFR+ NSCLC

October 23rd 2018

EP. 5: Adjuvant TKI for Early Stage EGFR+ NSCLC

October 23rd 2018

EP. 6: Updates in the Treatment of ALK+ and ROS1+ NSCLC

October 23rd 2018

EP. 7: Practice-Changing Frontline Treatment of ALK+ NSCLC

October 23rd 2018

EP. 8: Second Generation ALK Inhibitors in NSCLC

October 23rd 2018

EP. 9: Additional Targets in NSCLC: BRAF V600E and BRAF Variants

October 23rd 2018

EP. 10: NTRK Gene Fusions: Rare Yet Actionable

October 23rd 2018

EP. 11: Targeting HER2 Mutations in NSCLC: What Do We Know?

October 23rd 2018

EP. 12: Response Rates in Treatment of MET-Amplified NSCLC

October 23rd 2018

EP. 13: Advances in RET Inhibition in NSCLC

October 23rd 2018

EP. 14: Mutation Testing for All Patients With NSCLC

October 23rd 2018

Trending on OncLive

European Approval Is Sought for Lirafugratinib in FGFR2-Altered Metastatic Cholangiocarcinoma

FDA Approves Taletrectinib for Locally Advanced or Metastatic ROS1+ NSCLC

TUB-040 Elicits Clinically Meaningful Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

Dr Bianchi on the Mechanism of Anselamimab in AL Amyloidosis

Dr Kadia on Efficacy and Safety of Dibotatug in LGLL